Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

RGLS Regulus Therapeutics Inc

2,00

0,00 (0,00%)

Nach Börsenschluss

Zuletzt aktualisiert: 23:10:20

Verzögert um 15 Minuten

Form EFFECT - Notice of Effectiveness

Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Regulus Therapeutics Charts.

Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Regulus Therapeutics Charts.

News Regulus Therapeutics Inc

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 17 Mai 2024 (9 Minuten vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 17 Mai 2024 (41 Minuten vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 17 Mai 2024 (47 Minuten vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 17 Mai 2024 (52 Minuten vor) • Edgar (US Regulatory)

Form 8-K - Current report
Freitag 17 Mai 2024 (1 Stunde vor) • Edgar (US Regulatory)

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Donnerstag 16 Mai 2024 (1 Tag vor) • PR Newswire (US)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Donnerstag 9 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 9 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 9 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
Donnerstag 9 Mai 2024 (1 Woche vor) • PR Newswire (US)

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Montag 6 Mai 2024 (2 Wochen vor) • PR Newswire (US)

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Dienstag 30 April 2024 (2 Wochen vor) • PR Newswire (US)

Weitere Regulus Therapeutics Inc News-Artikel

Euro vs Sterling

BNP Paribas (QX)

JP Morgan Chase

Invesco QQQ Trust Series 1

Financial Select Sector

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen